Cancer clinical trials

Explore recruiting cancer clinical trials.

Recruiting cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open label randomized phase II/III trial of dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM)

Norway

Phase II and Phase III (Integrated) EU CTIS Study details

Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neo-adjuvant FOLFOXIRI and chemoradiotherapy for high risk (“ugly”) locally advanced rectal cancer.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)

France, Italy, Germany, Spain, Poland, Ireland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer trials by city

Cancer in Toronto Cancer in Vancouver Cancer in Montreal Cancer in Calgary Cancer in Edmonton Cancer in Ottawa Cancer in Winnipeg Cancer in Quebec City Cancer in Hamilton Cancer in Kitchener Cancer in London Cancer in Halifax Cancer in New York Cancer in Los Angeles Cancer in Chicago Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease